Cagrilintide: adverse events and evidence limits
A 26-week subcutaneous cagrilintide trial enrolled adults without diabetes with obesity, or overweight plus hypertension or dyslipidemia. Nausea, constipation, diarrhea and administration-site reactions occurred. [1]
Results span distinct study doses, rather than one reaction frequency. This abstract does not establish catalog-reagent safety. [1]
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Nausea | Adults without diabetes with obesity, or overweight plus hypertension or dyslipidemia, subcutaneous, 26 weeks | Reported; there is no single frequency — results span distinct study doses | [1] |
| Constipation | The same participants | Reported; no single frequency — results span distinct doses | [1] |
| Diarrhea | The same participants | Reported; no single frequency — results span distinct doses | [1] |
| Administration-site reactions | The same participants | Reported; no single frequency — results span distinct doses | [1] |
References
- David C W Lau et al. (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial https://doi.org/10.1016/S0140-6736(21)01751-7.